Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Enzalutamide on Oxycodone Pharmacokinetics in Men with Prostate Cancer
2020-005087-66Phase 4Active
- Sponsor
- Deventer Ziekenhuis
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Deventer Ziekenhuis. Primary endpoints: Oxycodone Cmax and Oxycodone AUC0-t. Started Dec 2020; status: active.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2020-005087-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005087-66.